Arrowhead Pharmaceuticals, Inc.

ARWR Healthcare Biotechnology

Arrowhead Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended September 2025) was $829.4 million, up 23,258.2% from fiscal 2024.

Revenue
+171.0%
EPS
−7.94%
Free cash flow
−15.4%
Total debt
+259.5%

Quarter to June 2026, against a year earlier

57.52 0.06 +0.10%
Market cap
$8.1B
P/E
0.0×
Fwd P/E
−16.6×
Dividend yield
—
F-score
5/9
Altman Z
2.98
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

(0.47%) 65.38% (46.90%) (64.91%)
Piotroski F-Score
— 6 — —
ROA
(0.13%) 15.45% (15.67%) (18.32%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(0.14%) 16.78% (15.68%) (18.16%)
Average Days of Receivables
3.00 73.23 9.20 4.66
Free Cash Flow per Share
1.17 2.35 (0.36) (0.52)
Free Cash Flow
156.89 322.01 (50.87) (75.11)
Other line items

Show all line items

Columns are period end dates